Portola May Need Randomized Trial For AndexXa Approval. The Question Is When
Executive Summary
Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.
You may also be interested in...
User Fee Forecast For May: Approvals Could Sprout In Multiple Divisions
Aimovig, Andexxa, Lucemyra, and pegvaliase are among the almost 20 products with upcoming user fee goals at US FDA this month.
Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial
In Bristol/Pfizer's ARISTOPHANES real-world study, the rate of major bleeding with Eliquis was 46% lower than J&J/Bayer's Xarelto and 33% lower than Boehringer's Pradaxa.
Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch
Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.